ClinicalTrials.gg
RecruitingNCT05772013OPACEUpdated Apr 3, 2024

Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations

A Phase 4 interventional study of Azithromycin Pill and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Dr Ian B Wilkinson. Recruiting at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Dr Ian B Wilkinson · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,311
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Azithromycin · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
Largest of 17
1,311 · median 92
Started
2024
the only one that year
Phase 4
4 of 17
1 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Dr Ian B Wilkinson

Among the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, this one has the largest planned enrollment, is the only one that started in 2024, is one of 4 in phase 4, and was the 17th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive is open now, in 1 country.

By country, each count listing its studies:

About azithromycin

Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

People living with chronic obstructive pulmonary disease (COPD) may experience worsening of symptoms such as shortness of breath, cough and wheezing in addition to changes that may be expected for having COPD. The worsening of symptoms is called exacerbations or flare-ups and can be debilitating and frightening, requiring additional treatment, often with azithromycin. This is an antibiotic medicine that also has anti-inflammatory properties. It is prescribed as long-term prevention to reduce the risk of flare-ups. Some people may be affected by side effects from azithromycin. Antibiotic resistance is another concern, especially when using azithromycin for prevention rather than to treat active infection.

It is currently unclear as to whether people should be advised to stop taking azithromycin once COPD has stabilised, or to stop it over the summer when fewer flare-ups happen. It is also not known if azithromycin is more effective in some people or more likely to cause side effects in others. Given these uncertainties, it is challenging to know how best to use azithromycin in managing COPD. Azithromycin is a valuable antibiotic, and should be prescribed where it has benefit but avoid unnecessary side effects and reduce the chances of bacteria becoming resistant to it.

The purpose of this trial is to be able to gain results to answer these questions, and to establish the effects of stopping azithromycin in people whose COPD has stabilised, who have been taking it for at least 3 months. This trial will compare continuing azithromycin with stopping it completely, or stopping over the summer only, continuing over the winter. The investigators will compare the effects of these three treatments in the trial on flare-ups, symptoms and quality of life, and find out what factors may affect how individual participants respond to them.

Read the detailed description

Background: Prophylactic azithromycin is recommended as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in people with COPD at high risk of exacerbations. In clinical practice, there is much uncertainty in how to optimally use this valuable treatment in managing COPD. It is unknown whether azithromycin is effective beyond one-year of treatment; what happens when azithromycin is discontinued following a period of use; or temporarily discontinued over the summer when there are fewer exacerbations. Whether there are differences in treatment responsiveness between subgroups of people with COPD is also uncertain.

Aim: To evaluate the benefits and risks of complete or seasonal discontinuation of azithromycin chemoprophylaxis vs continued treatment in people with stable COPD at high risk of exacerbations and assess effects in participant subgroups.

Methods: Design: A randomised double-blinded, non-inferiority, adaptive-design pragmatic trial of 3 parallel arms (complete discontinuation, vs seasonal discontinuation vs continued azithromycin as standard of care), to test the strategy of discontinuation of prophylactic azithromycin in participants with stable COPD at high risk of exacerbations. Internal pilot to evaluate recruitment will run for 9 months from first participant first visit (FPFV).

Randomisation allocation will be 1:1:1. Adaptive design means a treatment arm can be dropped if futile at interim analysis, but remaining arms continue.

Setting: General Practitioner (GP) practices, specialist community clinics, hospitals.

Target population: Stable COPD participants prescribed azithromycin ≥3 months to reduce risk of COPD exacerbations.

Interventions assessed: Complete discontinuation of azithromycin (matched placebo), seasonal discontinuation (azithromycin October-March, matched placebo April-September), continued azithromycin (standard of care).

Trial duration and procedures: Median follow up will be 24 months. Participants will have up to 3 visits - baseline, 12 months, 24 months/end of trial, which may coincide with standard of care visits and be in-person or remote depending on participant's individual preference. Telephone follow-up will be conducted at 1 week, 3 months, 6 months, and 18 months. All participants will have active follow up until study end, even if primary endpoint met. If participants have 3 or more exacerbations/year they will be advised to stop their trial medication. Participants may restart regular azithromycin prescription after stopping trial medication if advised by their GP/specialist. Secondary outcomes will be collected over the entire trial period and therefore may include evaluation both on and off trial medication.

Outcome measures:

Primary endpoint: Time to first exacerbation (TTFE) necessitating additional treatment with antibiotics and/or corticosteroids.

Key secondary endpoints (collected over entire trial)

  1. Number/rate and severity of exacerbations, length of exacerbation-free status
  2. Health related quality of life measured by change in the EuroQol-5 dimension
  3. Symptoms (COPD assessment tool (CAT) score and cough)
  4. Side effects
  5. Mortality
  6. Cost effectiveness from National Health Service (NHS) perspective.

Sample size: 1311 participants (437 per arm). Assuming a median TTFE of 150 days and non-inferiority threshold of 30 days shorter, equates to the threshold on the hazard ratio scale of 1.25. Sample size is based on 90 percent power for two non-inferiority comparisons (seasonal and placebo compared with continuous as standard treatment), at 2.7 percent significance using a Cox proportional hazards model. Pre-specified factors for subgroup analysis include exacerbation history, forced expiratory volume at one second (FEV1 percentage) predicted, current/ex-smoking status, COPD Assessment Tool (CAT) score, age, blood eosinophils.

Conclusion:

This pragmatic, real world trial aims to answer the uncertainties regarding prophylactic azithromycin use in COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Azithromycin
  • Chemoprophylaxis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able and willing to provide .
  • Have an established clinical diagnosis of and be receiving prophylactic azithromycin for ≥ (at least) 3 months to reduce COPD exacerbations.
  • Have a self-reported smoking history of ≥ (at least) 10 pack years.
  • Be aged >= 40 years.
  • Have clinically stable COPD, i.e. no COPD exacerbation for at least 6 weeks.

Exclusion criteria

Exclusion Criteria:

  • Known to any of the trial drugs or .
  • Current breast feeding, pregnancy or planned pregnancy during the trial.
  • Any medical history or abnormality that makes participant ineligible for inclusion because of a safety concern relating to continuing or discontinuing azithromycin or other considerations.
  • Known immunodeficiency requiring immunoglobulin/specific antibody therapy.
  • Azithromycin prophylaxis prescribed for non- condition.
  • Active participation in COPD Clinical Trial of an Medicinal Product (CTIMP).

(ECGs) will not be a trial assessment nor entry requirement.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,311 participants (estimated)

Study arms

  • Active comparator
    Continuous azithromycin

    Participants in this arm will continue with their standard of care (i.e. continuous dose of azithromycin according to their standard prescription) throughout the trial.

    Drug: Azithromycin Pill

  • Other
    Seasonal azithromycin

    Azithromycin will be taken by participants during the autumn-winter (October - March). Matched placebo will be taken by the participants in the spring-summer (April - September).

    Drug: Azithromycin Pill · Drug: Placebo

  • Placebo comparator
    Complete Discontinuation of azithromycin

    Participants will take continuous matched placebo throughout the trial.

    Drug: Placebo

Interventions

  • DrugAzithromycinStudies of AzithromycinAzithromycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will take azithromycin according to their standard of care prescription. If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September).

  • DrugPlacebo

    The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.

06

What researchers measure

Primary outcomes

  1. COPD exacerbation

    Time to first COPD exacerbation.

    Time frame: Throughout the entire trial follow-up of 24 months

Secondary outcomes

  1. Number and rate of exacerbations

    Number/rate of exacerbations (and differentiation by severity of exacerbations, i.e. requirement of hospitalisation)

    Time frame: Throughout the entire trial follow-up of 24 months

  2. Exacerbation-free period

    Duration of exacerbation-free status

    Time frame: Throughout the entire trial follow-up of 24 months

  3. Treatment for respiratory indication

    Antibiotics and/or corticosteroids use for respiratory indication

    Time frame: Throughout the entire trial follow-up of 24 months

  4. CAT Score

    Symptoms/impact: COPD Assessment Tool (CAT) score

    Time frame: Throughout the entire trial follow-up of 24 months

  5. Cough visual analogue scale (VAS) score

    The severity of the cough will be rated on a scale of 0 to 10, whereby 0 = no cough, 10 = worst cough

    Time frame: Throughout the entire trial follow-up of 24 months

  6. Health status

    Measured by change in quality of life questionnaire: A scale of 0-100 will be used, whereby 0 = Worst health imaginable, 100 = Best health imaginable

    Time frame: Throughout the entire trial follow-up of 24 months

  7. Mortality

    Mortality (all cause and specific)

    Time frame: Throughout the entire trial follow-up of 24 months

  8. Healthcare utilisation

    Details about the number of hospitalizations and primary care consultations will be recorded. There will be linkage with NHS England and equivalent services.

    Time frame: Throughout the entire trial follow-up of 24 months

  9. Adverse events of special interest (AESI) and Serious Adverse Reactions (SARs)

    AESI's include cardiovascular and hearing-defined as new prescription of hearing aids, liver function test (LFT) dysfunction). Serious adverse reactions (SARs) to be recorded as well.

    Time frame: Throughout the entire trial follow-up of 24 months

  10. Sputum culture results

    Sputum culture results will only be obtained if clinically indicated and sample via routine clinical care to local lab. Record if positive result (i.e. name of organism cultured only, not cfu/ml). If multiple sent, most recent one to trial visit should be used.

    Time frame: Throughout the entire trial follow-up of 24 months

  11. Adherence to trial medication

    Participants will be asked whether they have missed any doses of the trial medication, and if so, if they stopped taking it for longer than 2 weeks in duration and why. Participants will also be asked to return trial bottles and unused trial medication to the trial research team at their appointments.

    Time frame: Throughout the entire trial follow-up of 24 months

07

Study locations

1 of 1 sites recruiting
  • Cambridge University Hospital NHS Trust, Addenbrookes Hospital
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
    • Zehra Yilmaz, PhD · Contactzehra.yilmaz@nhs.net · 01223256599
    • Samuel Resendez, MSc · ContactSamuel.resendez@nhs.net · 01223 349 762
    • Jonathan Fuld, PhD · Principal investigator
    • Marie Fisk, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2028, 51 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 51 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 16, 2023
StartActual
Mar 5, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Nov 2028
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05772013
Lead sponsor
Dr Ian B Wilkinson
Collaborators
University of Aberdeen, NHS Greater Glasgow and Clyde, University of East Anglia, Nottingham City Hospital, Swansea University, Newcastle University, University of Cambridge, NHS Sunderland Clinical Commissioning Group, Liverpool School of Tropical Medicine, Royal Brompton & Harefield NHS Foundation Trust, University College London Hospitals, Liverpool Heart and Chest Hospital NHS Foundation Trust, Imperial College London, Red Graphic, Eramol (UK) Ltd., WGK Clinical Services Ltd., Sealed Envelope Ltd., National Institute for Health Research, United Kingdom
Responsible party
Dr Ian B Wilkinson (Professor of Therapeutics, Cambridge University Hospitals NHS Foundation Trust) — Sponsor-investigator
First posted
Mar 16, 2023
Start date
Mar 5, 2024
Primary completion
Jun 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Apr 3, 2024

Study contacts

Zehra T Yilmaz
Contact
zehra.yilmaz@nhs.net
+44 (0)1223 256599 ext. 6599
Heike Templin
Contact
heike.templin@nhs.net
+44 (01223 250874 ext. 0874
Ian B Wilkinson
study director · University of Cambridge & University of Cambridge NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azithromycin

Start the discussion